Moreover, favorable results about the synergistic antitumoral effect of the combination of OxPhos inhibitors and palbociclib in a triple-negative breast cancer cell line (66), encourage testing the use of this drug combination or OxPhos inhibitors alone in palbociclib-resistant PDX chordoma models harboring the CDKN2A/2B loss. Here, CDKN2A is linked to chordoma.